Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | HTR1A | P08908 | 6/20 | 0.49 |
| ▸ | DRD2 | P14416 | 1/20 | 0.49 |
| ▸ | LIPE | Q05469 | 1/20 | 0.47 |
| ▸ | LTA4H | P09960 | 1/20 | 0.46 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.46 |
| ▸ | ALPG | P10696 | 1/20 | 0.45 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.45 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.44 |
| ▸ | CDK1 | P06493 | 1/20 | 0.44 |
| ▸ | CDK4 | P11802 | 1/20 | 0.44 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.44 |
| ▸ | CCND1 | P24385 | 1/20 | 0.44 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.44 |
| ▸ | ADRA1D | P25100 | 3/20 | 0.42 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.42 |
| ▸ | ADRA1B | P35368 | 3/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1119402 | 0.88 | MAPT (0.51) | MAPTMAPK1TDP1L3MBTL1HTR1A | |
| SCHEMBL3767201 | 0.88 | HTR1A (0.49) | MAPTMAPK1TDP1L3MBTL1HTR1A | |
| SCHEMBL8732802 | 0.86 | MAPT (0.46) | MAPTMAPK1TDP1L3MBTL1HTR1A | |
| SCHEMBL27597893 | 0.85 | HTR1A (0.43) | MAPTMAPK1TDP1L3MBTL1HTR1A | |
| SCHEMBL28034423 | 0.84 | MAPT (0.40) | MAPTMAPK1TDP1L3MBTL1HTR1A | |
| SCHEMBL6614268 | 0.82 | NPC1 (0.52) | HTR1AADRA1DADRA1AADRA1BABCB1 | |
| SCHEMBL7294363 | 0.80 | L3MBTL1 (0.46) | MAPTMAPK1TDP1L3MBTL1HTR1A | |
| SCHEMBL7293597 | 0.80 | MAPT (0.59) | MAPTMAPK1TDP1L3MBTL1HTR1A | |
| SCHEMBL2721267 | 0.80 | HPGD (0.41) | MAPTMAPK1TDP1L3MBTL1HTR1A | |
| SCHEMBL7285309 | 0.80 | MAPT (0.50) | MAPTMAPK1TDP1L3MBTL1HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2002505318-A | — | — | 2002-02-19 | — | — | JP | claimed |
| US-6218426-B1 | FOR THERAPY OF MAMMALIAN REPRODUCTIVE DISORDERS AND STEROID HORMONE-DEPENDENT TUMORS AS WELL AS FOR REGULATING FERTILITY, WHERE SUPPRESSION OF GONADOTROPIN RELEASE IS INDICATED | AGOURON PHARMACEUTICALS, INC. | 2001-04-17 | — | — | US | claimed |
| EP-1068178-A1 | NON-PEPTIDE GnRH AGENTS | AGOURON PHARMACEUTICALS, INC. (US) | 2001-01-17 | — | — | EP | claimed |
| WO-1999044987-A1 | NON-PEPTIDE GnRH AGENTS | AGOURON PHARMACEUTICALS, INC. (US) | 1999-09-10 | — | — | WO | claimed |
| US-5877312-A | Method for preparing alkylating agents for their use for alkylating cyclic ureas | DUPONT PHARMACEUTICALS COMPANY (US) | 1999-03-02 | — | — | US | claimed |
| EP-0767770-A1 | METHOD FOR PREPARING ALKYLATING AGENTS AND THEIR USE FOR ALKYLATING CYCLIC UREAS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1997-04-16 | — | — | EP | claimed |
| WO-1996000708-A1 | METHOD FOR PREPARING ALKYLATING AGENTS AND THEIR USE FOR ALKYLATING CYCLIC UREAS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1996-01-11 | — | — | WO | claimed |
| WO-2023222124-A1 | 5,6-DIHYDRO-1,2,4-TRIAZINE COMPOUND AND PHARMACEUTICAL USE THEREOF AS GLP-1 RECEPTOR AGONIST | 中国科学院上海药物研究所 | 2023-11-23 | — | — | WO | disclosed |
| EP-2239057-B1 | Asymmetric catalyst and process for preparing optically active alcohols using the same | KANTO KAGAKU (JP) | 2015-06-03 | — | — | EP | disclosed |
| US-20140121213-A1 | VOLTAGE-GATED SODIUM CHANNEL BLOCKERS | GLAXO GROUP LIMITED (GB) | 2014-05-01 | — | — | US | disclosed |
| US-8563729-B2 | Thienopyridone derivatives as AMP-activated protein kinase (AMPK) activators | MERCK PATENT GMBH (DE) | 2013-10-22 | — | — | US | disclosed |
| US-8232420-B2 | Asymmetric catalyst and process for preparing optically active alcohols using the same | KANTO KAGAKU KABUSHIKI KAISHA (JP) | 2012-07-31 | — | — | US | disclosed |
| US-20120184693-A1 | ETHYLENE POLYMER PREPARATION METHOD | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-07-19 | — | — | US | disclosed |
| EP-0103945-B1 | SUBSTITUTED BENZENEDIOLS AND BENZODIOXINS | THE UPJOHN COMPANY (US) | 1988-04-20 | — | — | EP | disclosed |
| US-4631291-A | Enterobactin type compounds | Yeda Research & Development Co. Limited (IL) | 1986-12-23 | — | — | US | disclosed |
| US-4501892-A | Pyridyl benzenediols | THE UPJOHN COMPANY (US) | 1985-02-26 | — | — | US | disclosed |
| EP-0103945-A2 | Substituted benzenediols and benzodioxins | THE UPJOHN COMPANY (US) | 1984-03-28 | — | — | EP | disclosed |
| US-4176184-A | CARDIOTONICS, HYPOTENSIVES, ANTITHROMBOTICS AND ANTIARRHYTHMICS | BOEHRINGER INGELHEIM GMBH (DE) | 1979-11-27 | — | — | US | disclosed |
| US-3952021-A | α-(3,4-Dimethoxyphenethylaminomethyl)-3,4 or 3,5-dihydroxybenzylalcohols and salts thereof | TANABE SEIYAKU CO., LTD. (JA) | 1976-04-20 | — | — | US | disclosed |
| US-3952021-A | α-(3,4-Dimethoxyphenethylaminomethyl)-3,4 or 3,5-dihydroxybenzylalcohols and salts thereof | TANABE SEIYAKU CO., LTD. (JA) | 1976-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140121213-A1 | VOLTAGE-GATED SODIUM CHANNEL BLOCKERS | KCNB1, SCNN1B, TRPV1 | MAPT 2771/4885MAPK1 3555/4885TDP1 4465/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.